Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients with Relapsed/refractory Multiple Myeloma

Next Previous
Trial Profile

Phase I/II Clinical Study on Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients with Relapsed/refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Equecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms FUMANBA-1
  • Sponsors IASO BioMed; Nanjing IASO Biotechnology; Nanjing IASO Biotherapeutics

Most Recent Events

  • 18 Sep 2025 According to IASO BioMed media release, 36-month long-term follow-up data were presented at the 2025 International Myeloma Society (IMS) Annual Meeting
  • 18 Sep 2025 36-month long-term follow-up data from the FUMANBA-1 study published in the IASO BioMed Media Release
  • 28 Mar 2025 According to an IASO BioMed Media Release, company announced that the Pharmaceutical Administration Bureau of the Macao Special Administrative Region (ISAF) has approved the New Drug Application (NDA) for Equecabtagene Autoleucel based on data from the pivotal FUMANBA-1 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top